<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03387046</url>
  </required_header>
  <id_info>
    <org_study_id>MS200136_0041</org_study_id>
    <nct_id>NCT03387046</nct_id>
  </id_info>
  <brief_title>A Pilot Study in Subjects With Relapsing Remitting Multiple Sclerosis (RR-MS)</brief_title>
  <acronym>INCREASE</acronym>
  <official_title>Evaluation of clINical reCovery After a Relapse: a Pilot Study assEssing the Neuronal Effects of D-Aspartate in RR-MS Subjects Treated With IntErferon Beta 1a 44 mcg TIW (INCREASE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck KGaA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck KGaA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the improvement in spontaneous recovery from
      clinical deficits at the time of an acute relapse in RR-MS subjects already receiving
      interferon (IFN) beta 1a with D-aspartate (versus placebo) as add-on therapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 26, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Subjects With Change in Multiple Sclerosis Related Disability Measured by Functional Systems Scores of Expanded Disability Status Scale (EDSS)</measure>
    <time_frame>Week 8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Change in Multiple Sclerosis Related Disability Measured by Functional Systems Scores of EDSS</measure>
    <time_frame>Week 12 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Multiple Sclerosis Related Disability and Cognitive Impairment Measured by 25-foot Timed Walk (25-FWT)</measure>
    <time_frame>Week 8, 12 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Multiple Sclerosis Related Disability and Cognitive Impairment Measured by 9 Hole Peg Test (9HPT)</measure>
    <time_frame>Week 8, 12 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Multiple Sclerosis Related Disability and Cognitive Impairment Measured by Symbol Digit Modalities Test</measure>
    <time_frame>Week 8, 12 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Multiple Sclerosis Related Disability and Cognitive Impairment Measured by Low Contrast Letter visual Acuity Test</measure>
    <time_frame>Week 8, 12 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Fatigue Measured by Modified Fatigue Impact Scale (MFIS) Score</measure>
    <time_frame>Baseline, Week 8, 12 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Fatigue Measured by Fatigue Severity Scale (FSS) Score</measure>
    <time_frame>Baseline, Week 8, 12 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Long Term Potentiation Measured by Transcranial Magnetic Stimulation</measure>
    <time_frame>Baseline, Week 8, 12 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Treated Subjects With Immune-metabolic Response of Lymphocytes</measure>
    <time_frame>Baseline, Week 8 and 12</time_frame>
    <description>Immune-metabolic response of lymphocytes will be evaluated in treated subjects in vitro by Laboratory Assay.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Multiple Sclerosis, Relapsing-Remitting</condition>
  <arm_group>
    <arm_group_label>IFN beta-1a+Methylprednisolone+D-aspartate (MS with relapse)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>IFN beta-1a+Methylprednisolone+Placebo (MS with relapse)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>IFN beta-1a+D-aspartate (MS without relapse)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>IFN beta-1a+Placebo (MS without relapse)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>D-aspartate</intervention_name>
    <description>D-aspartate 2660 milligram (mg) once daily in the form of oral solution for 24 weeks.</description>
    <arm_group_label>IFN beta-1a+Methylprednisolone+D-aspartate (MS with relapse)</arm_group_label>
    <arm_group_label>IFN beta-1a+D-aspartate (MS without relapse)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matched to D-aspartate once daily in the form of oral solution for 24 weeks.</description>
    <arm_group_label>IFN beta-1a+Methylprednisolone+Placebo (MS with relapse)</arm_group_label>
    <arm_group_label>IFN beta-1a+Placebo (MS without relapse)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IFN beta-1a</intervention_name>
    <description>IFN beta-1a will be administered subcutaneously at a dose of 44 microgram (mcg) three times a week for 24 weeks.</description>
    <arm_group_label>IFN beta-1a+Methylprednisolone+D-aspartate (MS with relapse)</arm_group_label>
    <arm_group_label>IFN beta-1a+Methylprednisolone+Placebo (MS with relapse)</arm_group_label>
    <arm_group_label>IFN beta-1a+D-aspartate (MS without relapse)</arm_group_label>
    <arm_group_label>IFN beta-1a+Placebo (MS without relapse)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone</intervention_name>
    <description>Methylprednisolone 1000 mg will be administered intravenously once daily for 5 consecutive days.</description>
    <arm_group_label>IFN beta-1a+Methylprednisolone+D-aspartate (MS with relapse)</arm_group_label>
    <arm_group_label>IFN beta-1a+Methylprednisolone+Placebo (MS with relapse)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with RR-MS, according to the revised McDonald Criteria (2010)

          -  Subjects with an expanded disability status scale (EDSS) score between 0 and 3 before
             screening visit and before relapse

          -  Subjects receiving treatment with IFN beta 1a 44 mcg three times a week for at least 6
             months but for no more than 10 years before the screening visit

          -  Female subjects must be neither pregnant nor breastfeeding and must lack childbearing
             potential

          -  Subjects willing and able to comply with the protocol for the total duration of the
             study

          -  Subjects able to understand the purposes and the risks of the study

          -  Subjects have signed the appropriate written informed consent form, approved by the
             Independent Ethics Committee (IEC), prior to the performance of any study activities

          -  For MS subjects with relapse:

          -  Deterioration of at least one step in a relevant Functional Systems Scale (FSS) or an
             increase in EDSS of 1 point or more compatible, according to physician's judgment,
             with the therapy prosecution

          -  Relapse started within maximum 5 days before the inclusion in the study

          -  MS subjects without relapse with clinically stable RR-MS

        Exclusion Criteria:

          -  Subjects with diagnosis of primary progressive MS (PP-MS)

          -  Subjects have any disease other than MS that could better explain his/her signs and
             symptoms

          -  Subjects with any comorbidity with diseases that might alter synaptic plasticity
             (example Parkinson Disease, Alzheimer Disease, Stroke)

          -  Subjects receiving concomitant treatment with drugs that may alter synaptic plasticity
             (example, cannabinoids)

          -  Subjects with history or presence of any unstable medical condition (tumor or chronic
             infection or severe life threatening infection within the last 6 months)

          -  Subjects who have received any corticosteroids therapy within 3 months prior to the
             screening

          -  Subjects with any concomitant disease that may require chronic treatment with systemic
             corticosteroids or immunosuppressive agents during the course of the study

          -  Subjects who have received any immunosuppressive agents other to corticosteroids, as
             monotherapy or combination therapy within 3 months prior to the screening visit

          -  Subjects with history or currently active primary or secondary immunodeficiency

          -  Subjects with inadequate liver function, defined by alanine aminotransferase (ALT) &gt; 3
             * upper limit of normal (ULN), or alkaline phosphatase (AP) &gt; 2 * ULN, or total
             bilirubin &gt; 2 * ULN if associated with any elevation of ALT or AP

          -  Subjects with inadequate bone marrow reserve, defined as a white blood cell count less
             than 0.5 * lower limit of normal (LLN)

          -  Subjects with moderate to severe renal impairment

          -  Subjects unable to complete an magnetic resonance imaging (MRI) (contraindications for
             MRI include but are not restricted to weight &gt;=140 kilogram (kg), pacemaker, cochlear
             implants, presence of foreign substances in the eye, intracranial vascular clips,
             surgery within 6 weeks of entry into the study, coronary stent implanted within 8
             weeks prior to the time of the intended MRI, etc)

          -  Subjects with contraindication to gadolinium (Gd) can be enrolled into the study but
             cannot receive Gd contrast dyes during their MRI scans

          -  Subjects receiving supplements that, in the Investigator's opinion, may affect the
             evaluation of fatigue

          -  Subjects with any known contraindications or hypersensitivity to D-aspartate or any
             excipient

          -  Subjects with any other significant disease that in the Investigator's opinion would
             impede study assessments or endanger the subject

          -  Female subjects with positive pregnancy test at baseline or subjects with active
             project of pregnancy during the study

          -  Subjects with legal incapacity or limited legal capacity

          -  Subjects have participated in any other investigational study within 8 weeks before
             the screening visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Responsible</last_name>
    <role>Study Director</role>
    <affiliation>Merck KGaA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Merck KGaA Communication Center</last_name>
    <phone>+49 6151 72 5200</phone>
    <email>service@merckgroup.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Please Contact the Merck KGaA Communication Center</name>
      <address>
        <city>Darmstadt,</city>
        <zip>64293</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+49 6151 72 5200</phone>
      <email>service@merckgroup.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2017</study_first_submitted>
  <study_first_submitted_qc>December 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 29, 2017</study_first_posted>
  <last_update_submitted>April 13, 2018</last_update_submitted>
  <last_update_submitted_qc>April 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Relapsing remitting multiple sclerosis</keyword>
  <keyword>D-Aspartate</keyword>
  <keyword>interferon beta-1a</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Interferon-beta</mesh_term>
    <mesh_term>Interferon beta-1a</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>N-Methylaspartate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

